0728 GMT - Samsung Biologics is likely to benefit from rising contract development and manufacturing organization penetration, Nomura's analyst Cindy Park says in a research report. Nomura's view is partly based on strong global demand for large-scale contract manufacturing organizations, as pharmaceutical firms are increasingly transitioning into CDMOs to minimize risks related to high capex and uncertainties on drug approvals. CDMO penetration in global bio-pharmaceutical industry for mammalian cells will likely rise to 45% by 2030 from estimated 35% this year, with the South Korean contract development and manufacturing organization likely to be a key beneficiary. Nomura assumes coverage of the stock with a buy rating and a target price of KRW1,400,000.00. It previously held a neutral rating and a target price of KRW840,000.00. Shares closed 1.7% higher at KRW1,069,000.00. (ronnie.harui@wsj.com)
(END) Dow Jones Newswires
March 17, 2025 03:28 ET (07:28 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。